For GC patients, the incidence of FGFR2 amplification, FGFR2 fusion, and the cooccurrence of FGFR2 amplification and fusion were 18 (5.5%), 7 (2.1%), and 7 (2.1%) patients, respectively. This evidence concerns the gene FGFR2 and gastric cancer.